1. Impact of diabetes on clinical outcomes after revascularization with sirolimus-eluting and biolimus-eluting stents with biodegradable polymer from the SORT OUT VII trial.
- Author
-
Ellert J, Christiansen EH, Maeng M, Raungaard B, Jensen SE, Kristensen SD, Veien KT, Junker AB, Jakobsen L, Aarøe J, Terkelsen CJ, Kahlert J, Villadsen AB, Bøtker HE, and Jensen LO
- Subjects
- Acute Coronary Syndrome diagnostic imaging, Acute Coronary Syndrome mortality, Aged, Cardiovascular Agents adverse effects, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease mortality, Female, Humans, Male, Middle Aged, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention mortality, Prosthesis Design, Risk Assessment, Risk Factors, Sirolimus administration & dosage, Sirolimus adverse effects, Time Factors, Treatment Outcome, Absorbable Implants, Acute Coronary Syndrome therapy, Cardiovascular Agents administration & dosage, Coronary Artery Disease therapy, Diabetes Mellitus diagnosis, Diabetes Mellitus mortality, Drug-Eluting Stents, Percutaneous Coronary Intervention instrumentation, Polymers, Sirolimus analogs & derivatives
- Abstract
Objectives: In this substudy of the SORT OUT VII trial, the clinical outcomes among patient with diabetes mellitus treated with Orsiro sirolimus-eluting stent (O-SES; Biotronik, Bülach, Switzerland) or Nobori biolimus-eluting stent (N-BES; Terumo, Tokyo, Japan) were compared., Background: Diabetes is associated with increased risk of target lesion failure (TLF) after percutaneous coronary intervention., Methods: In total, 2525 patients were randomized to stent implantation with O-SES (n = 1261, diabetes: n = 236) or N-BES (n = 1264, diabetes: n = 235). The primary endpoint, TLF, was a composite of cardiac death, target-lesion myocardial infarction (MI), or target lesion revascularization (TLR) within 2 years., Results: At 2 year, TLF did not differ between O-SES vs N-BES in diabetic (9.3% vs 9.4%; RR 0.98, 95% CI 0.54-1.78) patients. The individual components of the primary endpoint did not differ among stent type. In diabetics, cardiac death occurred in 3% of O-SES-treated and in 3.8% of N-BES-treated patients (RR 0.77, 95% CI 0.29-2.08), MI occurred in 3.0% of O-SES-treated and in 3.8% of N-BES-treated patients (RR 0.76, 95% CI 0.28-2.06) and TLR occurred in 5,5% of O-SES-treated and in 6.0% of N-BES-treated patients (RR 0.91, 95% CI 0.43-1.95)., Conclusion: TLF did not differ between O-SES- and N-BES-treated diabetic patients., (© 2018 Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF